191. Improved Survival of Candida CLABSI by Adherence to Standard of Care and Involvement of Infectious Diseases Consultant: A 5-year Experience in a Single Academic Center
Session: Poster Abstract Session: Clinical Mycology
Thursday, October 5, 2017
Room: Poster Hall CD
Posters
  • Candidemia CLABSI poster- Final.pdf (33.4 kB)
  • Background: Candidemia is the 4th most common nosocomial blood stream infection with significant morbidity and mortality. Central lines have been considered a risk factor for invasive fungal infection. We evaluated the epidemiology, management and outcomes of Candida CLABSI in an academic medical center.

    Methods: We conducted a retrospective cohort study in a single academic center from January 1, 2011 to December 31, 2016 of patients who had positive blood cultures for Candida sp. and met CDC criteria for CLABSI. Outcomes measured were 30-day mortality and relapse or recurrence. Descriptive statistics were used to compare the outcomes of patients who had Infectious Diseases consult and managed per standard of care (SOC) as defined by IDSA guidelines and those without.

    Results: Of 722 CLABSI cases, 82 (11%) were due to Candida sp. Candida species isolated were as follows: C. glabrata (40%), C. albicans (32%), C. parapsilosis (9%), and others (19%).Median age of pediatric patients was 2.25 years (range 0.5-6) and median age of adults was 59 years (19-92). Most common comorbidities were malignancy (35%) and end stage renal disease (21%). Non-tunneled catheters were present in 58% of cases. Median time from line placement to candidemia was 15 days (IQR 8-29). Sepsis was present in 34 (42%) cases.

    Seventy-four (90%) cases were initiated on antifungal therapy (AFT) when culture turned positive. After Candida speciation, AFT was adjusted appropriately for 82 (100%) cases. IDC was present in 56 (68%), of which 41 (73%) followed SOC, whereas 15 (27%) did not. Two of 26 patients (8%) without IDC received SOC.

    Complications occurred in 11/82 (13%) (3 endocarditis, 2 osteomyelitis, 3 endophthalmitis and 4 septic thrombophlebitis). Cure was achieved in 26/82 (32%). Relapse or recurrence occurred in 15/82 (18%). The 30-day mortality for the cohort was 50%. Patients with IDC who received SOC had lower mortality compared to those who did not (35% vs 67%, respectively; p=0.03).

    Conclusion: Candida CLABSI was infrequent but had significant mortality in our cohort. Our results suggest that adherence to SOC per IDSA guidelines and involvement of IDC may improve survival of patients with Candida CLABSI. Future studies are needed to validate these findings.

    Blessy John, MD1, Maricar Malinis, MD, FACP, FIDSA2, Iyanna Fairweather, Infection Preventionist3, Michael Aniskiewicz, M(ASCP), CIC4, Jose Rivera- Vinas, Data Analysis Specialist5, Robert Baltimore, MD, FIDSA, FSHEA, FPIDS6 and Richard Martinello, MD2, (1)Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, (2)Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, (3)Infection Control, Yale New Haven Hospital, New Haven, CT, (4)Department of Infection Prevention, Yale New Haven Health System, New Haven, CT, (5)Quality Improvement and Safety, Yale New Haven Hospital, New Haven, CT, (6)Department of Pediatrics, Yale University School of Medicine, New Haven, CT

    Disclosures:

    B. John, None

    M. Malinis, None

    I. Fairweather, None

    M. Aniskiewicz, None

    J. Rivera- Vinas, None

    R. Baltimore, None

    R. Martinello, None

    See more of: Clinical Mycology
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.